Biotechnology company Spectrum Pharmaceuticals Inc (NASDAQ-GS:SPPI) revealed on Thursday the launch of a definitive agreement to divest its portfolio of seven products to Acrotech Biopharma LLC, a New Jersey-based wholly-owned subsidiary of Aurobindo Pharma USA Inc, for USD160m up-front cash payment.
In conjunction with the sale, Spectrum will receive up to USD140m in regulatory and sales-based milestones. The milestone period lasts for five years post the closing of the transaction, which is expected to close within 90 days.
Under the sale, the seven US FDA-approved hematology/oncology products include: FUSILEV (levoleucovorin), FOLOTYN (pralatrexate injection), ZEVALIN (ibritumomab tiuxetan), MARQIBO (vinCRIStine sulfate LIPOSOME injection), BELEODAQ (belinostat) for injection, EVOMELA (melphalan) for injection, and KHAPZORY (levoleucovorin). The products generated combined sales of USD76.4m during the first nine months of 2018.
However, the KHAPZORY milestones is only payable in the event KHAPZORY is assigned a unique J-code, added the company.
Following the acquisition, Spectrum's staff size will be reduced by approximately 40%, with the majority of impacted staff transitioning to Acrotech. Spectrum will retain a core group of commercial talent to lead the launch of ROLONTIS (eflapegrastim) and poziotinib.
The boards of directors of both the companies have approved the transaction, which is subject to regulatory approvals.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval